Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial
Harvard Medical School (HMS and HSDM)
Summary
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Description
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.
Eligibility
- Age range
- 18–99 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion criteria: * Age ≥ 18 years * Periodontally and systemically healthy * Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth) * Presence of single functional dental implant in the anterior with a PSTD * Implants diagnosed as healthy (Berglundh et al., 2018) Exclusion criteria are: * Contraindications for surgery * Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing * Patients pregnant or attempting to get pregnant (self-reported) * Untreated periodontitis * Untreated peri-implant mucositis or peri…
Interventions
- ProcedureVertical soft tissue augmentation
Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
- ProcedureVertical soft tissue augmentation
Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
Location
- Harvard School of Dental MedicineBoston, Massachusetts